Claimed effect · Afamelanotide (Melanotan I)

Does Afamelanotide (Melanotan I) help with pain-free sun exposure in erythropoietic protoporphyria?

A
Grade A — established in humans2 phase 3 RCTs (EU n=74, US n=94) · effect size: moderate
Short answerEstablished in humans. 2 phase 3 RCTs (EU n=74, US n=94) point the same way: a moderate effect. In both trials patients on afamelanotide implants spent significantly longer in direct sunlight without pain; the EU trial also counted fewer phototoxic reactions. Quality of life improved in both.

What the studies show

In both trials patients on afamelanotide implants spent significantly longer in direct sunlight without pain; the EU trial also counted fewer phototoxic reactions. Quality of life improved in both.

“In the U.S. study, the duration of pain-free time after 6 months was longer in the afamelanotide group (median, 69.4 hours, vs. 40.8 hours in the placebo group; P=0.04).”

Verbatim, from the abstractLangendonk JG, Balwani M, Anderson KE, et al. Afamelanotide for erythropoietic protoporphyria. N Engl J Med, 2015

Several well-run randomised trials in people, pointing the same way. You can plan around this. It still says nothing about whether the effect is worth the side effects for you.

  1. 1

In context

Afamelanotide is a linear analogue of the pigment hormone α-MSH, developed in the 1980s as the first 'Melanotan'. It is an approved medicine — as a subcutaneous implant replaced every two months — for erythropoietic protoporphyria, a genetic disorder in which sunlight causes severe pain within minutes. In two randomised trials it roughly doubled the hours patients could spend in direct sun without pain. The same molecule is sold illegally as a tanning injection; for that use there is no approval and no controlled evidence of safety.

Afamelanotide (Melanotan I) is approved (rx) — erythropoietic protoporphyria. Legal status differs by country — see the regulation section or the jurisdiction pages.

Questions

Is Afamelanotide (Melanotan I) proven to help with pain-free sun exposure in erythropoietic protoporphyria?
Yes, as far as human trials can show it: 2 phase 3 RCTs (EU n=74, US n=94). LYO grades this outcome A.
What studies are behind the grade?
In both trials patients on afamelanotide implants spent significantly longer in direct sunlight without pain; the EU trial also counted fewer phototoxic reactions. Quality of life improved in both.
Is Afamelanotide (Melanotan I) approved for this?
Afamelanotide (Melanotan I) is an approved medicine (Approved (Rx) — erythropoietic protoporphyria); whether this particular outcome is a licensed indication is stated on the compound page's regulation section.

Other outcomes for Afamelanotide (Melanotan I)

Written and maintained by LYO Research — how pages are written and checked. Reviewed 10 September 2026. Grades count human evidence only; see how LYO grades. Not medical advice. Correct this page →